Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)

Cell surface proteins that bind CALCITONIN GENE-RELATED PEPTIDE with high affinity and trigger intracellular changes which influence the behavior of cells. CGRP receptors are present in both the CENTRAL NERVOUS SYSTEM and the periphery. They are formed via the heterodimerization of the CALCITONIN RECEPTOR-LIKE PROTEIN and RECEPTOR ACTIVITY-MODIFYING PROTEIN 1.
Also Known As:
Calcitonin-Gene Related Peptide Receptor; Receptors, Calcitonin Gene-Related Peptide; CGRP Receptor; Calcitonin Gene Related Peptide Receptor; Calcitonin Gene Related Peptide Receptors; Receptors, Calcitonin Gene Related Peptide; CGRP Receptors; Receptors, CGRP
Networked: 307 relevant articles (50 outcomes, 47 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Edvinsson, Lars: 21 articles (08/2015 - 01/2002)
2. Goadsby, Peter J: 19 articles (10/2015 - 03/2004)
3. Salvatore, Christopher A: 15 articles (11/2015 - 10/2006)
4. Kane, Stefanie A: 13 articles (11/2015 - 01/2002)
5. Ho, Tony W: 11 articles (09/2014 - 12/2008)
6. Olesen, Jes: 10 articles (12/2015 - 03/2004)
7. Burgey, Christopher S: 10 articles (11/2015 - 10/2006)
8. Russo, Andrew F: 10 articles (06/2015 - 03/2007)
9. Paone, Daniel V: 9 articles (11/2015 - 09/2007)
10. Messlinger, Karl: 9 articles (01/2013 - 06/2006)

Related Diseases

1. Migraine Disorders (Migraine)
2. Headache (Headaches)
3. Pain (Aches)
4. Ischemia
11/01/2013 - "CGRP plays a role in protection against ischemia, but CGRP receptor antagonists do not seem to affect this protection to a harmfull extent, when used incidentally as acute antimigraine treatment. "
02/01/2009 - "This dose of CGRP((8-37)), administered either intravenously or intra-atrially, had no effect on ischemia severity or paced LAD flow, indicating no intrinsic effect of CGRP receptor antagonism on the severity of acute myocardial ischemia. "
01/01/2014 - "Finally, using both CGRP(8-37) (a CGRP receptor antagonist) and RP67580 (a SP receptor antagonist) to exclude the confounding effects of neuropeptides, we confirmed aforementioned detrimental effects as TRPV1(-/-) mouse hearts exhibited improved cardiac function during ischemia/reperfusion. "
12/06/2005 - "The hearts of gene-targeted TRPV1-null mutant (TRPV1(-/-)) mice or wild-type (WT) mice were perfused in a Langendorff apparatus in the presence or absence of capsazepine (a TRPV1 receptor antagonist), CGRP, CGRP(8-37) (a CGRP receptor antagonist), SP, or RP67580 (a neurokinin-1 [NK1] receptor antagonist) when hearts were subjected to 40 minutes of ischemia and 30 minutes of reperfusion. "
09/01/2007 - "Hearts of gene-targeted TRPV1-null mutant (TRPV1(-/-)) or wild-type (WT) mice were Langendorffly perfused in the presence or absence of CGRP(8-37), a selective calcitonin gene-related peptide (CGRP) receptor antagonist; or RP-67580, a selective neurokinin-1 receptor antagonist when hearts were subjected to three 5-min periods of ischemia PC followed by 30 min of global ischemia and 40 min of reperfusion (I/R). "
5. Cluster Headache (Cluster Headaches)

Related Drugs and Biologics

1. Calcitonin Gene-Related Peptide
2. olcegepant
3. N- (6- (2,3- difluorophenyl)- 2- oxo- 1- (2,2,2- trifluoroethyl)azepan- 3- yl)- 4- (2- oxo- 2,3- dihydro- 1H- imidazo(4,5- b)pyridin- 1- yl)piperidine- 1- carboxamide
4. BIBN 4096BS
5. Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)
6. Nitric Oxide Synthase (NO Synthase)
7. Neuropeptides
8. Nitroglycerin (Dynamite)
9. calcitonin gene-related peptide (8-37)
10. Antibodies

Related Therapies and Procedures

1. Therapeutics
2. Ligation
3. Intravenous Injections
4. Denervation
5. Vagotomy